Overview

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

An open-label, Phase 1b, dose escalation study evaluating the safety and tolerability of the PARP inhibitor Veliparib in combination with capecitabine and radiation in subjects with locally advanced rectal cancer (LARC).

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Capecitabine
Veliparib